|
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Angiopoietin-like protein 4: A therapeutic target for triglycerides and coronary disease?
|
29548670 |
2019 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Carriers of loss-of-function variants in ANGPTL3 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and LDL-C, while carriers of loss-of-function variants in ANGPTL4 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and increased HDL-C.
|
30893111 |
2019 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
One protein that raises plasma triglyceride levels and that has emerged as a modulator of coronary artery disease risk is angiopoietin-like 4 (ANGPTL4).
|
29555209 |
2019 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease.
|
29212778 |
2018 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to assess the association between the angiopoietin-like protein 4 gene (<i>ANGPTL4</i>) single nucleotide polymorphisms (SNPs) and serum lipid levels, the risk of coronary artery disease (CAD) and ischemic stroke (IS), and response to atorvastatin therapy in a Southern Chinese Han population.
|
30323852 |
2018 |
|
Coronary Artery Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease.
|
29713054 |
2018 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The 40Lys variant in ANGPTL4 was associated with protection from coronary disease and type 2 diabetes in groups with genetically higher or lower LDL-C. For a genetic difference of 0.23 SDs in LDL-C, ANGPTL3 loss-of-function variants, which also have beneficial associations with LPL lipolysis, were associated with greater protection against coronary disease than other LDL-C-lowering genetic mechanisms (ANGPTL3 loss-of-function variants: odds ratio, 0.66; 95% CI, 0.52-0.83; 58 LDL-C-lowering variants: odds ratio, 0.90; 95% CI, 0.89-0.91; P for heterogeneity = .009).
|
30326043 |
2018 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Inactivation of ANGPTL4 decreases plasma triglycerides and reduces the risk of coronary artery disease.
|
28412693 |
2017 |
|
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
We also found that: (i) beta-thalassemia trait carriers displayed lower TC and were protected from coronary artery disease (CAD); (ii) excluding the CETP locus, there was not a predictable relationship between plasma HDL-C and risk for age-related macular degeneration; (iii) only some mechanisms of lowering LDL-C appeared to increase risk for type 2 diabetes (T2D); and (iv) TG-lowering alleles involved in hepatic production of TG-rich lipoproteins (TM6SF2 and PNPLA3) tracked with higher liver fat, higher risk for T2D, and lower risk for CAD, whereas TG-lowering alleles involved in peripheral lipolysis (LPL and ANGPTL4) had no effect on liver fat but decreased risks for both T2D and CAD.
|
29083408 |
2017 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Association analyses based on false discovery rate implicate new loci for coronary artery disease.
|
28714975 |
2017 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We found that carriers of loss-of-function mutations in ANGPTL4 had triglyceride levels that were lower than those among noncarriers; these mutations were also associated with protection from coronary artery disease.
|
26934567 |
2016 |
|
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
CTD_human |
Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease.
|
27135400 |
2016 |
|
Coronary Artery Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Finally, we found that the expression of peroxisome proliferator-activated receptor δ (PPARδ), Adipose Differentiation-Related Protein (ADRP), and Angiopoietin-like 4 (ANGPTL4) were affected by LncPPARδ silencing.Our present study indicated that LncPPARδ, especially combined with risk factors, can be a good biomarker for CAD.
|
26871769 |
2016 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Carriers of E40K and other inactivating mutations in ANGPTL4 had lower levels of triglycerides and a lower risk of coronary artery disease than did noncarriers.
|
26933753 |
2016 |
|
Coronary Artery Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We examined the association of plasma ANGPTL4 levels with the metabolic syndrome (harmonized consensus definition), with angiographically determined coronary artery disease (CAD), and with the risk of future cardiovascular events in a cohort of 490 patients undergoing coronary angiography for the evaluation of stable CAD.
|
25463098 |
2014 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk.
|
20829508 |
2010 |
|
Coronary Artery Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study.
|
18940399 |
2008 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Based on this information, in this study we aimed to evaluate the relationship between serum ANGPTL-4 levels and obesity and hepatosteatosis in adolescents.
|
31419758 |
2020 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
One protein that raises plasma triglyceride levels and that has emerged as a modulator of coronary artery disease risk is angiopoietin-like 4 (ANGPTL4).
|
29555209 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Carriers of loss-of-function variants in ANGPTL3 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and LDL-C, while carriers of loss-of-function variants in ANGPTL4 have a reduced risk of coronary artery disease and reduced plasma levels of triglycerides and increased HDL-C.
|
30893111 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Furthermore, AGAP2-AS1 epigenetically inhibited the expression of ANKRD1 and ANGPTL4 by recruiting zeste homolog 2 (EZH2), thereby promoting PC proliferation and metastasis.
|
30814490 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Phillyrin lowers body weight in obese mice via the modulation of PPAR<beta>/<delta>-ANGPTL 4 pathway.
|
28320596 |
2019 |
|
Obesity
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the cross-sectional study, circulating ANGPTL-4 levels were lower in children with obesity than in those with normal weight.
|
31207920 |
2019 |
|
Obesity
|
0.400 |
Biomarker
|
disease |
BEFREE |
Obesity-associated inflammation promotes angiogenesis and breast cancer via angiopoietin-like 4.
|
30518876 |
2019 |
|
Coronary Arteriosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Angiopoietin-like 4 (ANGPTL4) is an endogenous inhibitor of lipoprotein lipase that modulates lipid levels, coronary atherosclerosis risk, and nutrient partitioning.
|
29899519 |
2018 |